Otsuka’s IgAN Data Top Some Vera Results, But To What End?

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.

Kidney
Otsuka and Vera are among the companies looking to bring new IgAN therapies to market

More from Strategy

More from Therapy Areas